EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK

被引：0
|
作者：
Rafia, R. [1 ]
Papaioannou, D. [1 ]
Stevenson, M. [1 ]
Rathbone, J. [1 ]
Woods, H. B. [1 ]
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1165
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A445 / A445
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Nam, J.
    Geirnaert, M.
    Milenkovski, R.
    Paulson, K.
    Yunger, S.
    Seftel, M.
    HAEMATOLOGICA, 2017, 102 : 296 - 296
  • [32] COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Nam, J.
    Milenkovski, R. B.
    Yunger, S.
    Geirnaert, M.
    Seftel, M.
    VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
  • [33] The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma
    Prettyjohns, Matthew
    Hoskin, Peter
    McNamara, Christopher
    Linch, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 52 - 59
  • [34] Cost-Effectiveness of Rituximab for Maintenance in Patients with Follicular Non-Hodgkin's Lymphoma in the Dutch Setting
    Pompen, Marjolein
    Huijgens, P. C.
    BLOOD, 2008, 112 (11) : 824 - 824
  • [35] Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada
    Johnston, Karissa M.
    Marra, Carlo A.
    Connors, Joseph M.
    Najafzadeh, Mehdi
    Sehn, Laurie
    Peacock, Stuart J.
    VALUE IN HEALTH, 2010, 13 (06) : 703 - 711
  • [36] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
  • [37] Cost-effectiveness and cost-utility of rituximab maintenance therapy for patients with relapsed/refractory follicular lymphoma in French setting
    Pacull, A.
    Coudray-Omnes, C.
    Brice, P.
    Deconinck, E.
    Le, Pen C.
    Miadi-Fargier, H.
    VALUE IN HEALTH, 2007, 10 (06) : A228 - A228
  • [38] Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL).
    Leppae, Sirpa
    Linna, Miika
    Nyman, Heidi
    Taimela, Eeva
    BLOOD, 2006, 108 (11) : 952A - 952A
  • [39] Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Rose, Adam C.
    Nastoupil, Loretta J.
    Flowers, Christopher R.
    BLOOD, 2013, 122 (21)
  • [40] A Cost-Effectiveness Analysis of Front-Line Treatment Strategies in Early Stage Follicular Lymphoma
    Tobin, Joshua W. D.
    Hapgood, Greg
    Gandhi, Maher K.
    Mollee, Peter
    Ma, Ti
    Crothers, Anna
    Scuffham, Paul
    BLOOD, 2020, 136
12345